Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.
<h4>Objective</h4>To assess whether the incidence of systemic adverse events differs between those who used bevacizumab and those who used ranibizumab in the treatment of age-related macular degeneration (AMD).<h4>Methods</h4>A systematic literature search was conducted to id...
Enregistré dans:
Auteurs principaux: | Wei Wang, Xiulan Zhang |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/18d4f918c97e45ed856a33bf575385c2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
par: Fischer N, et autres
Publié: (2013) -
Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
par: Dimitrios A Karagiannis, et autres
Publié: (2009) -
Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication
par: Damasceno N, et autres
Publié: (2012) -
Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
par: Canan H, et autres
Publié: (2014) -
Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration
par: Nishimura T, et autres
Publié: (2012)